Latest news

• Dupixent drives Sanofi again, but other new drugs are lagging

  There was a glimmer of acceleration for rheumatoid arthritis therapy Kevzara (sarilumab) which climbed 150% to 52m after several quarters of lacklustre performance.

• GSK pushes rheumatoid arthritis antibody into phase 3

  antibody Kevzara (sarilumab) and Pfizer’s JAK inhibitor Xeljanz (tofacitinib), to try to differentiate its drug.

• Hudson named Brandicourt’s successor as Sanofi’s CEO

  some trumpeted new launches like cholesterol drug Praluent (alirocumab) and arthritis drug Kevzara (sarilumab) have delivered on their potential.

• Alnylam swaps Sanofi for Regeneron as R&D partner

  that resulted in commercial products including cholesterol therapy Praluent (alirocumab), Dupixent (dupilumab) for atopic dermatitis and rheumatoid arthritis therapy Kevzara (sarilumab).

• Sanofi extends growth spurt thanks to Genzyme, Dupixent

  Other new products in Sanofi’s portfolio are still not looking too buoyant, particularly Kevzara (sarilumab) for rheumatoid arthritis and high cholesterol therapy Praluent (alirocumab), both of which have struggled to ... Sales of Kevzara in the US